Skip to Content

Pegfilgrastim Dosage

Applies to the following strength(s): 6 mg/0.6 mL

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for Febrile Neutropenia

6 mg subcutaneously once per chemotherapy cycle, beginning at least 24 hours after completion of chemotherapy; do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy

Use: To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia

Usual Adult Dose for Neutropenia Associated with Chemotherapy

6 mg subcutaneously once per chemotherapy cycle, beginning at least 24 hours after completion of chemotherapy; do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy

Use: To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia

Usual Adult Dose for Neutropenia Associated with Radiation

6 mg subcutaneously once a week for 2 doses

Comments:
-Administer the first dose as soon as possible after suspected or confirmed exposure to radiation levels greater than 2 gray (Gy) and administer the second dose one week after the first dose.
-A baseline complete blood count (CBC) should be obtained before dosing; however, therapy should not be delayed if a CBC is not readily available.
-The healthcare provider should estimate the level of radiation exposure in the patient based on information from public health authorities, biodosimetry if available, or clinical findings such as time to onset of vomiting or lymphocyte depletion kinetics.

Use: To increase survival in patients acutely exposed to myelosuppressive doses of radiation

Usual Pediatric Dose for Febrile Neutropenia

Doses are to be given subcutaneously once per chemotherapy cycle, beginning at least 24 hours after completion of chemotherapy; do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy:
Less than 10 kg: 0.1 mg/kg
10 to 20 kg: 1.5 mg
21 to 30 kg: 2.5 mg
31 to 44 kg: 4 mg
45 kg or greater: 6 mg

Comments:
-The prefilled syringe is not designed to allow administration of doses less than 0.6 mL (6 mg) because it does not have graduation marks, which are necessary to accurately measure doses less than 0.6 mL; therefore, administration to patients requiring less than 0.6 mL is not recommended.

Use: To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia

Usual Pediatric Dose for Neutropenia Associated with Chemotherapy

Doses are to be given subcutaneously once per chemotherapy cycle, beginning at least 24 hours after completion of chemotherapy; do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy:
Less than 10 kg: 0.1 mg/kg
10 to 20 kg: 1.5 mg
21 to 30 kg: 2.5 mg
31 to 44 kg: 4 mg
45 kg or greater: 6 mg

Comments:
-The prefilled syringe is not designed to allow administration of doses less than 0.6 mL (6 mg) because it does not have graduation marks, which are necessary to accurately measure doses less than 0.6 mL; therefore, administration to patients requiring less than 0.6 mL is not recommended.

Use: To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia

Usual Pediatric Dose for Neutropenia Associated with Radiation

Less than 10 kg: 0.1 mg/kg subcutaneously once a week for 2 doses
10 to 20 kg: 1.5 mg subcutaneously once a week for 2 doses
21 to 30 kg: 2.5 mg subcutaneously once a week for 2 doses
31 to 44 kg: 4 mg subcutaneously once a week for 2 doses
45 kg or greater: 6 mg subcutaneously once a week for 2 doses

Comments:
-Administer the first dose as soon as possible after suspected or confirmed exposure to radiation levels greater than 2 gray (Gy) and administer the second dose one week after the first dose.
-A baseline complete blood count (CBC) should be obtained before dosing; however, therapy should not be delayed if a CBC is not readily available.
-The healthcare provider should estimate level of radiation exposure in the patient based on information from public health authorities, biodosimetry if available, or clinical findings such as time to onset of vomiting or lymphocyte depletion kinetics.

Use: To increase survival in patients acutely exposed to myelosuppressive doses of radiation

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Data not available

Precautions

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Therapy should be initiated and supervised by physicians experienced in oncology and/or hematology.

General:
-This drug is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Hide